Univ of Nevada School of Med Research
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Madero, Priscilla
SIRIUS-SLE 1, NCT05639114 / 2022-002691-36: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus

Recruiting
3
406
Europe, Canada, Japan, US, RoW
Ianalumab, VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Systemic Lupus Erythematosus
01/27
04/29
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Recruiting
3
420
Europe, Canada, US, RoW
ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Lupus Nephritis
03/27
07/30
VE202-002, NCT05370885 / 2021-001280-24: VE202 in Patients with Mild-to-Moderate Ulcerative Colitis

Recruiting
2
100
Europe, US, RoW
VE202, Vancomycin Oral Capsule, VE202 Placebo, Vancomycin Placebo
Vedanta Biosciences, Inc.
Ulcerative Colitis, Colitis, Ulcerative
07/25
11/25
NCT03325855: Fecal Microbiota Transplant National Registry

Recruiting
N/A
4000
Canada, US
None - Observational, Observational
American Gastroenterological Association, OpenBiome, University of California, San Diego, Commure, University of Pennsylvania, University of Minnesota, Loyola University Chicago
Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
08/27
08/27

Download Options